Valerian sleep evidence is inconsistent, so it does not establish valerian as an effective treatment for chronic insomnia. NCCIH’s overview also separates apparent short-term safety from unknown long-term safety. Reported side effects, withdrawal after chronic use, and very rare liver-injury reports add important qualifications to its sleep-related claims.
When sleep has become difficult, an herb promoted for rest can sound appealing. Valerian’s long history and familiar name, however, cannot answer whether it reliably improves sleep or what ongoing use might mean for your health. The useful distinction is between three questions: whether it helps, what unwanted effects have been reported, and what remains unknown. This article explains the National Center for Complementary and Integrative Health’s summary of valerian research. It does not recommend a product, dose, course of use, or method for changing an existing supplement or treatment.
What does valerian sleep evidence establish for adults?
NCCIH describes inconsistent findings about valerian for sleep problems, rather than an established sleep benefit. This illustrates why understanding what research support can establish matters: a product’s intended purpose and the findings about that purpose are not the same thing.
Valerian is the plant Valeriana officinalis. Its roots and rhizomes are used medicinally; rhizomes are underground stems. NCCIH describes a history of medicinal use reaching back to ancient Greece and Rome. That history explains why valerian is familiar, but it is background information, not evidence that it treats insomnia.
NCCIH reports that the American Academy of Sleep Medicine’s 2017 clinical practice guideline recommended against valerian for chronic insomnia in adults. This describes the 2017 recommendation summarized by NCCIH, not a verification of all current guidance.
Inconsistent findings leave a meaningful limit: the summarized research does not provide a reliable basis for promising sleep improvement. They do not prove that every person or every preparation has been shown incapable of helping. Nor does one person’s report of sleeping better settle the broader effectiveness question.
The sleep conclusion also cannot be extended to mental health benefits. NCCIH separately finds insufficient evidence to draw conclusions about valerian for anxiety, depression, or stress. Promotion for several concerns does not create supporting evidence for each one.
What is known about valerian’s short-term and long-term safety?
NCCIH says research suggests valerian is generally safe for most adults over short-term use, while long-term safety remains unknown. Both parts belong together. Recognizing the limits of applying research findings to one person prevents that qualified observation from becoming a personal safety guarantee.
The NCCIH overview mentions use for up to six weeks with apparent safety under the conditions described. That is a report about prior use, not a recommended course. It does not establish that every amount, product, or combination is safe during that period.
Six weeks is also not a boundary at which safety suddenly changes. The statement does not identify a risk-free period followed by a known danger point. It describes the limits of the observation. Continuing use beyond a limited observation period raises questions that the short-term finding cannot resolve.
Tolerability and effectiveness answer different questions. A person might notice no unwanted effects without receiving a sleep benefit. Conversely, a perceived improvement would not establish that ongoing use is harmless. Neither experience fills the gap in long-term safety knowledge.
What effects on alertness, emotions and dreams are reported?
Valerian’s reported side effects include mental dullness, excitability, uneasiness, and vivid dreams, according to NCCIH. Understanding supplement effects and medicine interactions matters, as does separating research findings from an individual’s experience: noticing a change does not, by itself, prove benefit or identify its cause.
- Mental clarity: mental dullness describes feeling less mentally clear, not a demonstrated improvement in sleep.
- Activation or discomfort: excitability and uneasiness are listed effects, despite valerian’s promotion for rest.
- Dream experiences: vivid dreams concern how striking dreams feel, not proof of deeper or more restorative sleep.
- Physical discomfort: headache and stomach upset are also among the side effects NCCIH names.
These terms describe different experiences. Mental dullness should not be relabeled as beneficial relaxation. Likewise, vivid dreams do not establish a particular sleep stage or show that sleep quality improved. The overview supplies no basis for assigning those meanings to the reported effects.
Excitability and uneasiness also should not be interpreted as a psychiatric diagnosis. NCCIH’s list does not provide frequencies, an expected onset, or a mechanism explaining these effects. It cannot tell a reader whether a current feeling came from valerian, another product, or something unrelated.
NCCIH warns against taking valerian with alcohol or sedatives. Its stated reason preserves an important qualification: a sleep-inducing effect is possible but not proven. That caution is not evidence of established sleep effectiveness. The broader interaction topic is separate from whether valerian has demonstrated benefit for insomnia.
What do valerian withdrawal and liver-injury reports establish?
NCCIH identifies withdrawal reports after abrupt cessation following chronic use, and very rare liver-injury reports, most often involving other herbs. Neither supplies a personal risk estimate. Understanding why a suspected supplement problem does not establish its cause helps preserve those limits without assuming an interaction explains either concern.
Withdrawal reports have a specific context
The withdrawal passage in NCCIH’s overview concerns stopping abruptly after chronic use. It is not a description of what happens to everyone who tries valerian, and it should not be confused with the separate list of side effects during use. NCCIH names:
- Anxiety and irritability.
- Insomnia.
- Heart disturbances.
- Hallucinations, described as rare in this withdrawal context.
The list is not a diagnostic tool or a prediction. The overview does not say who will experience withdrawal or provide a stopping method. It cannot support instructions to taper, restart, or substitute another substance. Heart disturbances and hallucinations should not be dismissed as ordinary difficulty sleeping simply because they appear in this passage.
Liver reports leave attribution unresolved
NCCIH describes liver-injury reports as very rare, most often when valerian was taken with other herbs. “Very rare” is the agency’s qualitative description, not a numerical estimate of an individual’s risk. The involvement of other herbs makes it harder to assign responsibility to one ingredient.
That uncertainty cuts both ways. It does not establish valerian as the culprit, but it also does not establish that valerian used alone is harmless. Separately, NCCIH says valerian’s long-term effect on liver function is unknown. Uncertainty about reported injuries and uncertainty about ongoing liver effects are related but distinct gaps.
The following comparison keeps the different findings in NCCIH’s valerian summary separate.
| Finding described by NCCIH | What it tells us | What it does not establish |
|---|---|---|
| Inconsistent sleep findings | The summary does not establish a reliable sleep benefit. | Universal ineffectiveness for every person or preparation. |
| Apparent short-term safety | A qualified observation concerns limited use. | Long-term safety, personal suitability, or sleep effectiveness. |
| Withdrawal reports after chronic use | Symptoms have been reported after abrupt cessation in that context. | Who will experience withdrawal or how an individual should stop. |
| Liver-injury reports, most often involving other herbs | A safety concern includes uncertainty about attribution. | A proven culprit or assurance that valerian alone is harmless. |
For immediate danger or a life-threatening emergency, call 911. For suicide or crisis support, call or text 988, as described by NIMH. Crisis support does not replace emergency medical care. MVBH is an adult outpatient provider, not an emergency service.
Can these findings identify a valerian product that works?
No. The overview does not identify a commercial preparation with established benefit or give enough product detail to make that match. The principle of keeping an evidence claim tied to the approach studied matters here: naming an ingredient is not the same as demonstrating that a particular product works.
The botanical name and plant parts help identify what valerian means. They do not answer which preparation, if any, has demonstrated a dependable sleep benefit. NCCIH’s valerian overview does not supply comparative sleep findings for teas, capsules, extracts, or different administration routes. It therefore cannot support a ranking among them.
NCCIH’s general supplement guidance adds one bounded caution: products sold in stores or online may differ in important ways from products tested in studies. This does not establish a defect in a particular valerian brand. It explains why a shared ingredient name alone cannot bridge the gap between a research product and a retail purchase.
For an adult dealing with sleep and mental health concerns, these findings can inform care without selecting treatment. NIMH emphasizes that mental health treatment should reflect individual needs and medical circumstances under professional guidance. That principle does not establish valerian as a treatment or turn this evidence summary into personal supplement instructions.
Written by Tim Francis, SUD Content Specialist. This article is educational and does not provide diagnosis, prescribing advice, or a supplement-use or withdrawal-management plan.
Frequently asked questions
Does valerian’s long history show that it works for sleep?
No. Historical use shows that people have used valerian medicinally for a long time, not that it reliably improves sleep. NCCIH presents that history separately from its conclusion that sleep findings are inconsistent. Familiarity cannot resolve the effectiveness question or establish the safety of ongoing use.
Is the 2017 recommendation a statement about all current guidance?
No. NCCIH’s overview reports that the American Academy of Sleep Medicine recommended against valerian for adult chronic insomnia in its 2017 guideline. That supports an accurately dated statement about the recommendation. It does not verify every current guideline or establish that a new review of the original guideline occurred for this article.
Does apparent safety for up to six weeks create a safe-use deadline?
No. The period mentioned by NCCIH describes prior use with apparent safety under particular conditions. It is not a recommended duration, a guarantee for an individual, or a point before which adverse effects cannot occur. The same overview explicitly leaves long-term safety unknown.
Do valerian withdrawal reports establish an addiction diagnosis?
No. NCCIH reports withdrawal symptoms following abrupt cessation after chronic use, but that passage does not establish an addiction diagnosis. It also does not say that everyone using valerian chronically will experience those symptoms. The reports cannot diagnose a reader’s experience or supply instructions for changing use.
Does the alcohol warning mean valerian is a proven sedative?
No. NCCIH’s warning explicitly says a sleep-inducing effect is possible but not proven, and advises against taking valerian with alcohol or sedatives. A precaution can be important even when an effect remains uncertain. The warning should not be converted into a claim that valerian reliably induces sleep.
